Developer docs
API playgroundTry for free, no card

Search company profiles

Bicara Therapeutics

Full company profile

uuid00007lr

Namestring
Bicara Therapeutics
Legal namestring
Bicara Therapeutics, Inc.
Websiteurl
bicara.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing ficerafusp alfa (BCA101), a first-in-class bifunctional antibody designed to simultaneously target the EGFR receptor on tumor cells and modulate TGF-β signaling in the tumor microenvironment. Its lead clinical focus is first-line treatment of HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in combination with Merck's pembrolizumab, supported by FDA Breakthrough Therapy Designation granted in October 2024 and the pivotal Phase 3 FORTIFI-HN01 trial. The company plans to broaden the asset into additional solid tumor indications including metastatic colorectal cancer.

Bicara has no approved products and generates no commercial revenue today; its economic model is anchored on future pharmaceutical sales of ficerafusp alfa upon regulatory approval in the United States, supplemented by potential licensing and royalty income in additional indications or territories. Capital is being deployed to build a US specialty-pharmacy and field-sales distribution channel targeting oncologists and head/neck specialists at major cancer centers, with commercial infrastructure work accelerated by a February 2026 follow-on public offering and the May 2026 appointment of a Chief Commercial Officer with nine prior oncology launches.

Founded in 2018 as a Biocon spinout, Bicara has raised approximately $807.5 million across a Series B, Series C, a $362 million September 2024 Nasdaq IPO, and follow-on offerings in 2026, ending Q1 2026 with $539.8 million in cash to fund operations into 2029. The company is headquartered in Boston, Massachusetts, employs 51-100 people, and reports FY 2025 and Q1 2026 net losses of $137.95 million and $56.2 million respectively, consistent with late-stage clinical development and pre-launch investment.

Short descriptiontext

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a first-in-class bifunctional EGFR/TGF-β antibody, for HPV-negative head and neck squamous cell carcinoma in combination with pembrolizumab, with broader solid tumor expansion plans.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bifunctional antibody therapy, oncology drug development, head and neck cancer treatment, tumor microenvironment modulators, EGFR TGF-beta antibody
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical drug sales
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company with no current revenue, Bicara Therapeutics plans to generate revenue through commercial sales of its drug candidates, primarily ficerafusp alfa upon FDA approval. The company is building commercial infrastructure to support potential launch.

fool.com
2Drug licensing and partnerships
TypeLicensing Royalties
Description

Future potential revenue from licensing agreements for ficerafusp alfa in additional indications or territories.

fool.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Marketing or Sales, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional antibody therapies that combine tumor-targeting antibodies with tumor microenvironment modulators. Its lead product candidate, ficerafusp alfa (BCA101), is a dual-action EGFR/TGF-β antibody being developed for solid tumor cancers, with primary focus on HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab. The candidate is in late-stage clinical development (pivotal Phase 3 FORTIFI-HN01) and has received FDA Breakthrough Therapy Designation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 31% overall survival at 3 years with 1500mg weekly dose of ficerafusp alfa plus pembrolizumab
+4 more records
Product overview1 text field

Bicara Therapeutics is a clinical-stage biotechnology company developing a single lead product: ficerafusp alfa (BCA101), a first-in-class bifunctional EGFR/TGF-β antibody. The company is focused on developing this novel biologic therapy for the treatment of solid tumors, with primary emphasis on head and neck squamous cell carcinoma (HNSCC). The product is currently in late-stage clinical trials (Phase 2/3 FORTIFI-HN01 pivotal trial) and has received FDA Breakthrough Therapy Designation for first-line HPV-negative recurrent/metastatic HNSCC in combination with pembrolizumab.

Product and service1 record
1Ficerafusp alfa (BCA101)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Biocon incubated Bicara Therapeutics and is its founding partner. Claire Mazumdar, CEO of Bicara, is the niece of Biocon founder Kiran Mazumdar-Shaw. Bicara is positioned as Biocon's succession vehicle and innovation arm for novel biologics development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ficerafusp alfa is being developed in combination with pembrolizumab (Keytruda) from Merck. Bicara has received FDA Breakthrough Therapy Designation for this combination therapy in first-line HPV-negative recurrent/metastatic HNSCC.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies for oncology, including DART platform molecules targeting solid and hematologic tumors. Directly comparable to Bicara's bifunctional antibody approach and oncology-focused pipeline.

TypeDirect peer
Description

Pioneer in bispecific antibody technology (Duobody platform) with approved oncology assets including Rybrevant and Tecvayli. Closely comparable business model as a bispecific-antibody-focused oncology company.

TypeDirect peer
Description

Clinical-stage oncology biotech developing bispecific antibodies (Biclonics and Triclonics platforms), including petosemtamab in HNSCC. Direct competitor in both bispecific antibody technology and HNSCC indication.

TypeDirect peer
Description

China-based biotech with a leading bispecific antibody pipeline including ivonescimab (PD-1/VEGF), a novel dual-mechanism oncology biologic. Directly comparable as a clinical-stage bispecific antibody developer.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company with U.S. rights to toripalimab (Loqtorzi), an approved PD-1 inhibitor for nasopharyngeal carcinoma and under review for additional HNSCC indications. Direct competitor in the HNSCC immuno-oncology space.

TypeBroad incumbent
Description

Established oncology and immunology company with approved bispecific antibodies including Linvoseltamab and REGN-COV. Broader portfolio, but overlapping bispecific antibody platform technology and immuno-oncology focus.

TypeBroad incumbent
Description

Large incumbent with extensive oncology portfolio including EGFR/HER2 inhibitors and immuno-oncology assets relevant to HNSCC. Overlaps with Bicara through EGFR targeting and checkpoint combination strategies, though operates at vastly greater scale across many therapeutic areas.

TypeBroad incumbent
Description

Developer of pembrolizumab (Keytruda), Bicara's combination partner and the dominant 1L HNSCC standard of care. Strategic partner but also a competitive threat given the breadth of Merck's oncology pipeline.

TypeEmerging player
Description

Clinical-stage immuno-oncology biotech developing adenosine receptor and checkpoint inhibitors in combinations, including for HNSCC. Comparable as a smaller-cap oncology biotech pursuing combination immunotherapy strategies.

TypeEmerging player
Description

Clinical-stage precision medicine oncology biotech developing targeted therapies including MAT2A and DNA damage response inhibitors. Comparable as a similarly-sized clinical-stage oncology company with a focused pipeline and public-market profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bicara Therapeutics

Oncology Biopharmaceuticalsbicara.com

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a first-in-class bifunctional EGFR/TGF-β antibody, for HPV-negative head and neck squamous cell carcinoma in combination with pembrolizumab, with broader solid tumor expansion plans.

What Bicara Therapeutics does

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing ficerafusp alfa (BCA101), a first-in-class bifunctional antibody designed to simultaneously target the EGFR receptor on tumor cells and modulate TGF-β signaling in the tumor microenvironment. Its lead clinical focus is first-line treatment of HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in combination with Merck's pembrolizumab, supported by FDA Breakthrough Therapy Designation granted in October 2024 and the pivotal Phase 3 FORTIFI-HN01 trial. The company plans to broaden the asset into additional solid tumor indications including metastatic colorectal cancer.

Bicara has no approved products and generates no commercial revenue today; its economic model is anchored on future pharmaceutical sales of ficerafusp alfa upon regulatory approval in the United States, supplemented by potential licensing and royalty income in additional indications or territories. Capital is being deployed to build a US specialty-pharmacy and field-sales distribution channel targeting oncologists and head/neck specialists at major cancer centers, with commercial infrastructure work accelerated by a February 2026 follow-on public offering and the May 2026 appointment of a Chief Commercial Officer with nine prior oncology launches.

Founded in 2018 as a Biocon spinout, Bicara has raised approximately $807.5 million across a Series B, Series C, a $362 million September 2024 Nasdaq IPO, and follow-on offerings in 2026, ending Q1 2026 with $539.8 million in cash to fund operations into 2029. The company is headquartered in Boston, Massachusetts, employs 51-100 people, and reports FY 2025 and Q1 2026 net losses of $137.95 million and $56.2 million respectively, consistent with late-stage clinical development and pre-launch investment.

Bicara Therapeutics firmographics

Firmographics
Name
Bicara Therapeutics
Legal name
Bicara Therapeutics, Inc.
Website
https://bicara.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a first-in-class bifunctional EGFR/TGF-β antibody, for HPV-negative head and neck squamous cell carcinoma in combination with pembrolizumab, with broader solid tumor expansion plans.
Ownership category
akta.pro rank

Bicara Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Bifunctional antibody therapy
  • Oncology drug development
  • Head and neck cancer treatment
  • Tumor microenvironment modulators
  • EGFR TGF-beta antibody

Where Bicara Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bicara Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel

Revenue model

  1. Pharmaceutical drug sales: As a clinical-stage biopharmaceutical company with no current revenue, Bicara Therapeutics plans to generate revenue through commercial sales of its drug candidates, primarily ficerafusp alfa upon FDA approval. The company is building commercial infrastructure to support potential launch.
  2. Drug licensing and partnerships: Future potential revenue from licensing agreements for ficerafusp alfa in additional indications or territories.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Bicara Therapeutics product offering

Product offering

Core offering

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional antibody therapies that combine tumor-targeting antibodies with tumor microenvironment modulators. Its lead product candidate, ficerafusp alfa (BCA101), is a dual-action EGFR/TGF-β antibody being developed for solid tumor cancers, with primary focus on HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab. The candidate is in late-stage clinical development (pivotal Phase 3 FORTIFI-HN01) and has received FDA Breakthrough Therapy Designation.

Product overview

Bicara Therapeutics is a clinical-stage biotechnology company developing a single lead product: ficerafusp alfa (BCA101), a first-in-class bifunctional EGFR/TGF-β antibody. The company is focused on developing this novel biologic therapy for the treatment of solid tumors, with primary emphasis on head and neck squamous cell carcinoma (HNSCC). The product is currently in late-stage clinical trials (Phase 2/3 FORTIFI-HN01 pivotal trial) and has received FDA Breakthrough Therapy Designation for first-line HPV-negative recurrent/metastatic HNSCC in combination with pembrolizumab.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ficerafusp alfa (BCA101)

Quantifiable outcome

  • 31% overall survival at 3 years with 1500mg weekly dose of ficerafusp alfa plus pembrolizumab
  • +4 more outcomes

Companies that use Bicara Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Bicara Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Bicara Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BioconcoreStrategic or Co-development Partner · 1 September 2024Biocon incubated Bicara Therapeutics and is its founding partner. Claire Mazumdar, CEO of Bicara, is the niece of Biocon founder Kiran Mazumdar-Shaw. Bicara is positioned as Biocon's succession vehicle and innovation arm for novel biologics development.
  • Merck (Pembrolizumab partnership)coreStrategic or Co-development PartnerFicerafusp alfa is being developed in combination with pembrolizumab (Keytruda) from Merck. Bicara has received FDA Breakthrough Therapy Designation for this combination therapy in first-line HPV-negative recurrent/metastatic HNSCC.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Bicara Therapeutics competitors and assessment

Company assessment

Direct peers

  • MacroGenics: Clinical-stage biotech developing bispecific antibodies for oncology, including DART platform molecules targeting solid and hematologic tumors. Directly comparable to Bicara's bifunctional antibody approach and oncology-focused pipeline.
  • Genmab: Pioneer in bispecific antibody technology (Duobody platform) with approved oncology assets including Rybrevant and Tecvayli. Closely comparable business model as a bispecific-antibody-focused oncology company.
  • Merus: Clinical-stage oncology biotech developing bispecific antibodies (Biclonics and Triclonics platforms), including petosemtamab in HNSCC. Direct competitor in both bispecific antibody technology and HNSCC indication.
  • Akeso: China-based biotech with a leading bispecific antibody pipeline including ivonescimab (PD-1/VEGF), a novel dual-mechanism oncology biologic. Directly comparable as a clinical-stage bispecific antibody developer.
  • Coherus BioSciences: Commercial-stage biopharmaceutical company with U.S. rights to toripalimab (Loqtorzi), an approved PD-1 inhibitor for nasopharyngeal carcinoma and under review for additional HNSCC indications. Direct competitor in the HNSCC immuno-oncology space.

Broad incumbents

  • Regeneron Pharmaceuticals: Established oncology and immunology company with approved bispecific antibodies including Linvoseltamab and REGN-COV. Broader portfolio, but overlapping bispecific antibody platform technology and immuno-oncology focus.
  • AstraZeneca: Large incumbent with extensive oncology portfolio including EGFR/HER2 inhibitors and immuno-oncology assets relevant to HNSCC. Overlaps with Bicara through EGFR targeting and checkpoint combination strategies, though operates at vastly greater scale across many therapeutic areas.
  • Merck & Co. Developer of pembrolizumab (Keytruda), Bicara's combination partner and the dominant 1L HNSCC standard of care. Strategic partner but also a competitive threat given the breadth of Merck's oncology pipeline.

Emerging players

  • Arcus Biosciences: Clinical-stage immuno-oncology biotech developing adenosine receptor and checkpoint inhibitors in combinations, including for HNSCC. Comparable as a smaller-cap oncology biotech pursuing combination immunotherapy strategies.
  • IDEAYA Biosciences: Clinical-stage precision medicine oncology biotech developing targeted therapies including MAT2A and DNA damage response inhibitors. Comparable as a similarly-sized clinical-stage oncology company with a focused pipeline and public-market profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Bicara Therapeutics social profiles

Digital presence

Bicara Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bicara Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Bicara Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bicara Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bicara Therapeutics

What does Bicara Therapeutics do?

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional antibody therapies that combine tumor-targeting antibodies with tumor microenvironment modulators. Its lead product candidate, ficerafusp alfa (BCA101), is a dual-action EGFR/TGF-β antibody being developed for solid tumor cancers, with primary focus on HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab. The candidate is in late-stage clinical development (pivotal Phase 3 FORTIFI-HN01) and has received FDA Breakthrough Therapy Designation.

Is Bicara Therapeutics a public or private company?

Bicara Therapeutics is a public company. It is classified as public and is currently operating.

When was Bicara Therapeutics founded?

Bicara Therapeutics was founded in 2018. It employs 101 to 250 people.

Where is Bicara Therapeutics based?

Bicara Therapeutics is headquartered in Boston, United States, in the North America region.

How does Bicara Therapeutics make money?

Two revenue lines are on record. Pharmaceutical drug sales are the primary driver. The others are drug licensing and partnerships.

Who are Bicara Therapeutics's main competitors?

Direct peers on record are MacroGenics, Genmab, Merus, Akeso and Coherus BioSciences. Broad incumbents are Regeneron Pharmaceuticals, AstraZeneca and Merck & Co.. Emerging players are Arcus Biosciences and IDEAYA Biosciences.

Does Bicara Therapeutics have an API?

No public API is recorded for Bicara Therapeutics.

What industry is Bicara Therapeutics in?

Bicara Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TimeClaire Mazumdar: TIME100 Next India 2026Claire Mazumdar co-founded Bicara to develop an antibody that targets two molecules, including one that suppresses immune response to tumors. The drug's lead immunotherapy product is preparing for late-stage human studies in head and neck cancer. She will become adviser and vice chair of Bicara's board and is named potential successor to Biocon, a $6 billion biopharma company.YahooBicara Therapeutics (BCAX) Stock Gets Fair Value Trim As Analysts Split On FiceraBicara Therapeutics' Fair Value fell from $35.67 to $32.17, reflecting a split in analyst views on its ficera drug. Bullish firms cite the oncology pipeline, while bearish ones point to tighter peak share assumptions and competition. The company also entered a sublease for its new Boston headquarters.TradingViewHC Wainwright & Co. maintains Bicara Therapeutics at Buy, lowers price target to $36 from $42HC Wainwright & Co. maintained Bicara Therapeutics at Buy and lowered its price target to $36 from $42, a 14.3% decrease. The target implies an upside of 253.6% from the Nov 10 close of $10.18. Recent analyst price targets on the stock range from $8 to $43.Defense WorldBicara Therapeutics (NASDAQ:BCAX) Price Target Cut to $30.00 by Analysts at Morgan StanleyMorgan Stanley cut its price target on Bicara Therapeutics to $30 from $41, keeping an overweight rating. The company reported a Q3 loss of $1.04 per share, missing the $0.82 consensus estimate. Analysts have a consensus rating of Moderate Buy with an average price target of $30.83.Defense WorldBicara Therapeutics (NASDAQ:BCAX) Stock Price Target Lowered at Stifel NicolausStifel Nicolaus lowered its Bicara Therapeutics price target to $43 from $45, keeping a buy rating. The company reported a Q3 loss of $1.04 per share, missing estimates, and CEO Ryan Cohlhepp sold 17,500 shares. Bicara expects trial results in mid-2027 and has $442.3 million in cash.Investing.comCitizens reiterates Bicara Therapeutics stock rating on trial progressCitizens reiterated a Market Outperform rating and $31 price target on Bicara Therapeutics, citing trial progress and cash position. The stock trades at $9.98, below its 52-week high of $30.99, with initial metastatic colorectal cancer data expected in January 2027. Bicara reported $442.3 million in cash and $56.5 million in R&D spending.MarketScreenerBicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Bicara Therapeutics reported a Q3 net loss of $71.25 million and a nine-month net loss of $182.9 million, both higher than the prior year. Basic and diluted loss per share from continuing operations were $1.04 and $2.78, respectively, compared to $0.67 and $1.84 a year ago.